retatrutide phase 2 trial results clinical data Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with Retatrutide study sees significant weight

Per quanto riguarda la sicurezza, gli effetti collaterali pi comuni dei GLP-1 RA sono di natura gastrointestinale, inclusi nausea, vomito, costipazione, diarrea, che si verificano nel 40%-65% dei pazienti

One received selenium (100 g twice daily), while the second was given pentoxifylline (an anti-inflammatory agent) at a dose of 600 mg twice daily, or a placebo (twice daily) orally, for six months

Singh TD, Patial K, Vijayan VK, Ravi K

Neurotrauma 28, 18131825

However, these findings strongly support that GLP-1RAs do not increase the risk of intestinal obstruction compared to non-GLP-1RA anti-diabetic medications